[vc_row el_class=”breadcrumbs”][vc_column][vc_column_text][\/vc_column_text][\/vc_column][\/vc_row][vc_section el_class=”start-ups”][vc_row][vc_column width=”1\/2″][vc_column_text el_class=”management-section”]MANAGEMENT:<\/span>\u00a0Barney Koszalka TRPblue has developed small molecule antagonists that preferentially attenuate signaling of these calcium-permeable channels with proven efficacy in several acute pain and chemical denervation nerve-pain models. These inhibitors have also demonstrated anti-pruritic, anti-fibrotic and anti-inflammatory activity in relevant preclinical models. The team will develop a topically applied, highly tolerated go-to dermatology therapeutic.[\/vc_column_text][\/vc_column][vc_column width=”1\/2″][vc_single_image image=”372″ img_size=”full”][\/vc_column][\/vc_row][vc_row css=”.vc_custom_1535394535521{padding-top: 15px !important;}”][vc_column][vc_column_text]<\/p>\n [\/vc_column_text][vc_column_text]<\/p>\n [\/vc_column_text][\/vc_column][\/vc_row][vc_row css=”.vc_custom_1535395083641{padding-top: 20px !important;}”][vc_column][vc_separator][\/vc_column][\/vc_row][\/vc_section]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":" Developing a unique, dual acting inhibitor that targets transient receptor potential (TRP) cation channels TRPV4 and TRPA1<\/p>\n","protected":false},"author":26,"featured_media":373,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_exactmetrics_skip_tracking":false,"footnotes":""},"categories":[4],"tags":[],"class_list":["post-371","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-startups"],"acf":[],"_links":{"self":[{"href":"https:\/\/numbers.otc.duke.edu\/2018-report\/wp-json\/wp\/v2\/posts\/371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/numbers.otc.duke.edu\/2018-report\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/numbers.otc.duke.edu\/2018-report\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/numbers.otc.duke.edu\/2018-report\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/numbers.otc.duke.edu\/2018-report\/wp-json\/wp\/v2\/comments?post=371"}],"version-history":[{"count":13,"href":"https:\/\/numbers.otc.duke.edu\/2018-report\/wp-json\/wp\/v2\/posts\/371\/revisions"}],"predecessor-version":[{"id":699,"href":"https:\/\/numbers.otc.duke.edu\/2018-report\/wp-json\/wp\/v2\/posts\/371\/revisions\/699"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/numbers.otc.duke.edu\/2018-report\/wp-json\/wp\/v2\/media\/373"}],"wp:attachment":[{"href":"https:\/\/numbers.otc.duke.edu\/2018-report\/wp-json\/wp\/v2\/media?parent=371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/numbers.otc.duke.edu\/2018-report\/wp-json\/wp\/v2\/categories?post=371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/numbers.otc.duke.edu\/2018-report\/wp-json\/wp\/v2\/tags?post=371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nDUKE INVENTOR:<\/span> Wolfgang Liedtke[\/vc_column_text][vc_column_text]A therapeutics company developing a unique, dual acting inhibitor that targets transient receptor potential (TRP) cation channels TRPV4 and TRPA1.<\/p>\nTHE PROBLEM:<\/h3>\n
THE SOLUTION:<\/h3>\n